NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Tarsus reported financial results for the third quarter of 2023, marked by the successful launch of XDEMVY® and significant revenue generation from net product sales.
Tarsus Pharmaceuticals announced its Q3 2023 financial results, highlighting the successful launch of XDEMVY® which generated $1.7 million in net product sales. The company's total revenues reached $1.9 million. Despite increased R&D and SG&A expenses, Tarsus ended the quarter with a strong cash position of $246.9 million.
- Launched XDEMVY® (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis treatment.
- Achieved $1.7 million in net product sales with over 1,700 bottles dispensed.
- Secured approximately $100 million through a public equity offering.
- XDEMVY was added to the American Academy of Ophthalmology’s Preferred Practice Pattern guidelines.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$1.87M
Forward guidance
Tarsus Pharmaceuticals anticipates securing broad commercial coverage for XDEMVY sequentially throughout 2024 and Medicare coverage in 2025.
Tailwinds
- Continued disease education efforts to drive awareness among eye care providers.
- Ongoing contract discussions with key commercial and Medicare accounts.
- Expect to secure broad commercial coverage sequentially throughout 2024.
- Medicare coverage anticipated in 2025.
- Advancing pipeline to address diseases with high unmet need.
Headwinds
- Incurred significant losses and negative cash flows from operations since inception.
- Anticipates continuing to incur significant expenses and losses for the foreseeable future.
- May need to obtain additional funding to complete the development and commercialization of product candidates.
- Heavily dependent on the success of XDEMVY for the treatment of Demodex blepharitis.
- Sizes of the market opportunity for XDEMVY and product candidates have not been established with precision and may be smaller than estimated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro